Abstract：
OBJECTIVE: Determining the concentration of prestin in human blood, cerebrospinal fluid (CSF), and perilymph (PL), and evaluating its suitability as a clinical biomarker for sensori-neural hearing loss (SNHL).
METHODS: Human blood, CSF, and PL samples were intraoperatively collected from 42 patients with tumors of the internal auditory canal or with intracochlear tumors undergoing translabyrinthine or middle fossa tumor removal. Prestin concentration was measured using enzyme-linked immunosorbent assay and linear regression analyses were performed to investigate its associations with audiological as well as vestibular test results.
METHODS: Tertiary referral center.
RESULTS: The median prestin concentration in blood samples of the 42 study participants (26 women, mean ± standard deviation age, 52.7 ± 12.5 years) was 1.32 (interquartile range, IQR, 0.71-1.99) ng/mL. CSF prestin levels were significantly higher with 4.73 (IQR, 2.45-14.03) ng/mL (P = .005). With 84.74 (IQR, 38.95-122.00) ng/mL, PL prestin concentration was significantly higher compared to blood (P = .01) and CSF (P = .03) levels. Linear regression analyses showed significant associations of CSF prestin concentration with preoperative hearing levels (pure-tone average and word recognition; P = .008, R2 = 0.1894; P = .03, R2 = 0.1857), but no correlations with blood or PL levels.
CONCLUSIONS: This study\'s findings highlight the volatile nature of prestin levels and provide the first insights into this potential biomarker\'s concentrations in body fluids apart from blood. Future investigations should comprehensively assess human prestin levels with different etiologies of SNHL, prestin\'s natural homeostasis and systemic circulation, and its temporal dynamics after cochlear trauma. Finally, clinically approved detection kits for prestin are urgently required prior to considering a potential translational implementation of this diagnostic technique.
METHODS: Human blood, CSF, and PL samples were intraoperatively collected from 42 patients with tumors of the internal auditory canal or with intracochlear tumors undergoing translabyrinthine or middle fossa tumor removal. Prestin concentration was measured using enzyme-linked immunosorbent assay and linear regression analyses were performed to investigate its associations with audiological as well as vestibular test results.
METHODS: Tertiary referral center.
RESULTS: The median prestin concentration in blood samples of the 42 study participants (26 women, mean ± standard deviation age, 52.7 ± 12.5 years) was 1.32 (interquartile range, IQR, 0.71-1.99) ng/mL. CSF prestin levels were significantly higher with 4.73 (IQR, 2.45-14.03) ng/mL (P = .005). With 84.74 (IQR, 38.95-122.00) ng/mL, PL prestin concentration was significantly higher compared to blood (P = .01) and CSF (P = .03) levels. Linear regression analyses showed significant associations of CSF prestin concentration with preoperative hearing levels (pure-tone average and word recognition; P = .008, R2 = 0.1894; P = .03, R2 = 0.1857), but no correlations with blood or PL levels.
CONCLUSIONS: This study\'s findings highlight the volatile nature of prestin levels and provide the first insights into this potential biomarker\'s concentrations in body fluids apart from blood. Future investigations should comprehensively assess human prestin levels with different etiologies of SNHL, prestin\'s natural homeostasis and systemic circulation, and its temporal dynamics after cochlear trauma. Finally, clinically approved detection kits for prestin are urgently required prior to considering a potential translational implementation of this diagnostic technique.
摘要：
目的：测定人血液中prestin的浓度，脑脊液（CSF），和外淋巴(PL)，并评估其作为感觉神经性听力损失（SNHL）临床生物标志物的适用性。
方法：人血，CSF,术中收集42例内听道肿瘤或耳蜗内肿瘤患者的PL样本。使用酶联免疫吸附测定法测量Prestin浓度，并进行线性回归分析以研究其与听力学和前庭测试结果的关联。
方法：三级转诊中心。
结果：42名研究参与者（26名女性，平均值±标准差年龄，52.7±12.5年)为1.32(四分位数间距，IQR,0.71-1.99)ng/mL。CSFprestin水平显着高于4.73（IQR，2.45-14.03）ng/mL（P=0.005）。与84.74（IQR，38.95-122.00)ng/mL,PLprestin浓度显著高于血液(P=.01)和CSF(P=.03)水平。线性回归分析显示，CSFprestin浓度与术前听力水平（纯音平均值和单词识别；P=.008，R2=0.1894；P=.03，R2=0.1857）显着相关，但与血液或PL水平无关。
结论：这项研究的发现突出了prestin水平的挥发性，并首次揭示了这种潜在的生物标志物在除血液以外的体液中的浓度。未来的调查应全面评估具有不同病因的SNHL的人类prestin水平，Prestin的自然稳态和体循环，以及耳蜗损伤后的时间动态.最后,在考虑该诊断技术的潜在转化实施之前，迫切需要临床批准的Prestin检测试剂盒。
方法：人血，CSF,术中收集42例内听道肿瘤或耳蜗内肿瘤患者的PL样本。使用酶联免疫吸附测定法测量Prestin浓度，并进行线性回归分析以研究其与听力学和前庭测试结果的关联。
方法：三级转诊中心。
结果：42名研究参与者（26名女性，平均值±标准差年龄，52.7±12.5年)为1.32(四分位数间距，IQR,0.71-1.99)ng/mL。CSFprestin水平显着高于4.73（IQR，2.45-14.03）ng/mL（P=0.005）。与84.74（IQR，38.95-122.00)ng/mL,PLprestin浓度显著高于血液(P=.01)和CSF(P=.03)水平。线性回归分析显示，CSFprestin浓度与术前听力水平（纯音平均值和单词识别；P=.008，R2=0.1894；P=.03，R2=0.1857）显着相关，但与血液或PL水平无关。
结论：这项研究的发现突出了prestin水平的挥发性，并首次揭示了这种潜在的生物标志物在除血液以外的体液中的浓度。未来的调查应全面评估具有不同病因的SNHL的人类prestin水平，Prestin的自然稳态和体循环，以及耳蜗损伤后的时间动态.最后,在考虑该诊断技术的潜在转化实施之前，迫切需要临床批准的Prestin检测试剂盒。
